Company Insights

VSTM customer relationships

Explore interactive graphBrowse insights index

VSTM customers relationship map

Verastem (VSTM): Licensing-driven revenue, concentrated counterparty exposure

Verastem is a development-stage oncology biopharma that monetizes intellectual property through licensing transactions and milestone-based receipts rather than high-volume product sales. The company realized material revenue in FY2024 from the sale of an exclusive worldwide license for its duvelisib-containing assets (COPIKTRA) and a triggered sales milestone tied to the licensee’s commercial performance; this commercial posture defines Verastem’s near-term cash flow profile and investor risk calculus. For a deeper look at counterparty particulars and implications, visit https://nullexposure.com/.

One license defines the commercial picture

Verastem’s operating model is oriented around monetizing R&D assets via outbound licensing rather than vertically integrated commercialization. In August–September 2020 Verastem executed an Asset Purchase Agreement (APA) transferring an exclusive worldwide license for development, commercialization and manufacture of duvelisib-containing oncology products to Secura, and the transaction remains an active revenue driver: Secura’s reported COPIKTRA sales hit a milestone threshold that generated a $10.0 million payment to Verastem in July 2024. According to Verastem’s FY2024 Form 10‑K, the sale and subsequent milestone payment were the single material revenue event tied to that counterparty (Verastem 10‑K, fiscal year ended December 31, 2024).

Key takeaway: Verastem’s near-term topline is materially dependent on license monetization and milestone mechanics rather than recurring product sales.

The explicit relationships (what the filings state)

  • Secura Bio, Inc. — Verastem sold an exclusive worldwide license and related assets for the research, development, commercialization, and manufacture of duvelisib-containing oncology products, and recorded revenue associated with the transaction and milestones. According to Verastem’s FY2024 Form 10‑K, the Secura APA closed on September 30, 2020 and the license sale and related milestone payments produced recognized revenue in the 2024 period (Verastem 10‑K, vstm-2024-12-31).

  • Secura — The FY2024 10‑K discloses a significant concentration of revenue: for the years ended December 31, 2024 and 2022, Secura was the single customer that individually accounted for all of the Company’s revenue. That filing also notes Secura achieved $100.0 million of total worldwide net sales of COPIKTRA in 2024, triggering the $10.0 million milestone payment to Verastem that was received in July 2024 (Verastem 10‑K, vstm-2024-12-31).

These two entries are complementary reflections of the same commercial arrangement: Secura Bio, Inc. as the legal counterparty to the Secura APA, and the accounting disclosure that Secura represented 100% of reported revenue in specific years.

How the filing-derived constraints shape the business model

The 10‑K disclosures provide direct signals about Verastem’s contracting posture, geographic reach, role in the transaction, and the developmental stage of the relationship:

  • Contracting posture — licensing. The transaction is an asset and exclusive license sale; Verastem operates as a seller of IP and related assets rather than the commercializing manufacturer. The 10‑K explicitly references the sale of the COPIKTRA license and related assets and associated revenue in 2024 (Company 10‑K, FY2024).

  • Geographic reach — global rights granted. The APA conveyed an exclusive worldwide license, indicating that Verastem relinquished global commercial rights for the specified oncology uses.

  • Role — seller of IP. Verastem’s role in the arrangement is as the transferor of developed assets and the payer/recipient of milestone receipts tied to the licensee’s sales performance.

  • Relationship stage — active and monetizing. Although the APA closed in 2020, the relationship remains commercially relevant: Secura’s COPIKTRA sales in 2024 triggered a milestone payment that Verastem received in July 2024, evidencing an active, monetizing agreement.

Taken together, these constraints describe a company whose current cash inflows are episodic, counterparty-dependent, and governed by contractual milestones rather than stable product revenues.

Concentration and criticality — why investors must pay attention

Verastem’s FY2024 filings identify a single counterparty concentration: Secura accounted for all revenue in at least two reported years. That concentration is material in the context of Verastem’s scale — Revenue TTM reported at roughly $30.9 million while the single milestone in 2024 was $10.0 million — so license-related cash flow can move reported revenue materially from year to year. The combination of exclusive worldwide licensing and milestone-linked receipts creates both upside (lump-sum payments when thresholds are met) and fragility (revenue falls away if licensee sales contract or contractual triggers are not met).

Investor implications: evaluate counterparty credit and commercialization execution at Secura, monitor future milestone mechanics or contingent consideration in filings, and treat Verastem’s revenue run-rate as non-recurring until the company demonstrates diversified, repeatable revenue streams.

Relationship summaries (concise, filing-backed)

  • Secura Bio, Inc.: Verastem sold exclusive worldwide rights and related assets for duvelisib-containing oncology products under the Secura APA, a transaction that generated recorded revenue and milestone receipts for Verastem; the APA closed September 30, 2020 and is detailed in Verastem’s FY2024 10‑K (vstm-2024-12-31).

  • Secura: The FY2024 10‑K states that Secura accounted for all of Verastem’s revenue in both 2024 and 2022, and that Secura’s $100.0 million of COPIKTRA net sales in 2024 triggered a $10.0 million milestone payment to Verastem, received in July 2024 (Verastem 10‑K, vstm-2024-12-31).

Practical next steps for investors and operators

  • For investors: prioritize monitoring subsequent filings for additional milestone activity, changes in contractual economics, or new licensing transactions that reduce single-customer concentration. Assess Secura’s commercial trajectory for COPIKTRA—its sales performance directly drives Verastem receipts.
  • For corporate counterparties and operators: understand that Verastem’s commercial engagement model is structured to monetize IP through single-license exits and milestone economics; negotiation of future deals will likely follow similar mechanics unless strategic direction changes.

If you want structured visibility into counterparty relationships and revenue concentration across public filings, explore our platform at https://nullexposure.com/ for curated relationship intelligence and filing-level detail.

Bold, simple facts from the 10‑K drive the story: Verastem sells IP globally, relies on licensee execution for revenue milestones, and recorded material revenue in FY2024 tied to a single licensee. Those are the drivers investors must model and monitor.

Join our Discord